- An eye drug biotech banks $118M and stocks its executive suite<figure><div><img src="https://imgproxy.divecdn.com/cIH1PfJposjsKezbbrmwTwtzNlhqTiIaZ_OaEGGTHE8/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjE5NzI0MTUxLmpwZ…BioPharma Dive · 3h ago↗ source
- The FDA was all in on AI. Will that change?<figure><div><img src="https://imgproxy.divecdn.com/SbY7pjJU5zpd9fYni9dr5J14qHlA98Kk2ofoQajpOLE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9UVFIyNUguanBn.webp"/></div></figur…BioPharma Dive · 3h ago↗ source
- Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder winAn experimental drug targeting both GLP-1 and glucagon receptors has curbed heavy drinking in a phase 2 trial, providing hope that the ubiquitous weight loss meds can be effectively harnessed again…